{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:56:15Z","timestamp":1790834175734,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L000644\/1"],"award-info":[{"award-number":["MR\/L000644\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_14111"],"award-info":[{"award-number":["MC_PC_14111"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_16052"],"award-info":[{"award-number":["MC_PC_16052"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106240\/Z\/14\/Z"],"award-info":[{"award-number":["106240\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Primaquine (PQ) is an essential antimalarial drug but despite being developed over 70 years ago, its mode of action is unclear. Here, we demonstrate that hydroxylated-PQ metabolites (OH-PQm) are responsible for efficacy against liver and sexual transmission stages of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    . The antimalarial activity of PQ against liver stages depends on host CYP2D6 status, whilst OH-PQm display direct, CYP2D6-independent, activity. PQ requires hepatic metabolism to exert activity against gametocyte stages. OH-PQm exert modest antimalarial efficacy against parasite gametocytes; however, potency is enhanced ca.1000 fold in the presence of cytochrome P450 NADPH:oxidoreductase (CPR) from the liver and bone marrow. Enhancement of OH-PQm efficacy is due to the direct reduction of quinoneimine metabolites by CPR with the concomitant and excessive generation of H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    , leading to parasite killing. This detailed understanding of the mechanism paves the way to rationally re-designed 8-aminoquinolines with improved pharmacological profiles.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-11239-0","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T06:03:00Z","timestamp":1563516180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Antimalarial activity of primaquine operates via a two-step biochemical relay"],"prefix":"10.1038","volume":"10","author":[{"given":"Grazia","family":"Camarda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyaporn","family":"Jirawatcharadech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-5326","authenticated-orcid":false,"given":"Richard S.","family":"Priestley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8110-0916","authenticated-orcid":false,"given":"Michael H. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suet","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-8933","authenticated-orcid":false,"given":"David A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Alano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-7713","authenticated-orcid":false,"given":"Mark J. I.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta N.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-6595","authenticated-orcid":false,"given":"Giancarlo A.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"11239_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A., Recht, J. & White, N. J. Primaquine: the risks and the benefits. Malar. J. 13, 418 (2014).","journal-title":"Malar. J."},{"key":"11239_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","volume":"161","author":"SR Marcsisin","year":"2016","unstructured":"Marcsisin, S. R., Reichard, G. & Pybus, B. S. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharm. Ther. 161, 1\u201310 (2016).","journal-title":"Pharm. Ther."},{"key":"11239_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archinte.1962.03620140081013","volume":"109","author":"AR Tarlov","year":"1962","unstructured":"Tarlov, A. R., Brewer, G. J., Carson, P. E. & Alving, A. S. Primaquine sensitivity: glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch. Intern. Med. 109, 209\u2013234 (1962).","journal-title":"Arch. Intern. Med."},{"key":"11239_CR4","first-page":"413","volume":"59","author":"A Strother","year":"1981","unstructured":"Strother, A., Fraser, I. M., Allahyari, R. & Tilton, B. E. Metabolism of 8-aminoquinoline antimalarial agents. Bull. World Health Organ. 59, 413\u2013425 (1981).","journal-title":"Bull. World Health Organ."},{"key":"11239_CR5","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1016\/S0021-9258(19)50504-X","volume":"267","author":"J V\u00e1squez-Vivar","year":"1992","unstructured":"V\u00e1squez-Vivar, J. & Augusto, O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J. Biol. Chem. 267, 6848\u20136854 (1992).","journal-title":"J. Biol. Chem."},{"key":"11239_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","volume":"44","author":"N Vale","year":"2009","unstructured":"Vale, N., Moreira, R. & Gomes, P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44, 937\u2013953 (2009).","journal-title":"Eur. J. Med. Chem."},{"key":"11239_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1172\/JCI82981","volume":"126","author":"R Raphemot","year":"2016","unstructured":"Raphemot, R., Posfai, D. & Derbyshire, E. R. Current therapies and future possibilities for drug development against liver-stage malaria. J. Clin. Investig. 126, 2013\u20132020 (2016).","journal-title":"J. Clin. Investig."},{"key":"11239_CR8","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1301936","volume":"369","author":"JW Bennett","year":"2013","unstructured":"Bennett, J. W. et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. New Engl. J. Med. 369, 1381\u20131382 (2013).","journal-title":"New Engl. J. Med."},{"key":"11239_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.taap.2009.07.012","volume":"241","author":"S Ganesan","year":"2009","unstructured":"Ganesan, S., Tekwani, B. L., Sahu, R., Tripathi, L. M. & Walker, L. A. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol. Appl. Pharmacol. 241, 14\u201322 (2009).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"11239_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-259","volume":"11","author":"BS Pybus","year":"2012","unstructured":"Pybus, B. S. et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar. J. 11, 259 (2012).","journal-title":"Malar. J."},{"key":"11239_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-424","volume":"11","author":"WHOMPA Committee","year":"2012","unstructured":"Committee, W. H. O. M. P. A. & Secretariat Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar. J. 11, 424 (2012).","journal-title":"Malar. J."},{"key":"11239_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.chom.2013.06.005","volume":"14","author":"S March","year":"2013","unstructured":"March, S. et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 14, 104\u2013115 (2013).","journal-title":"Cell Host Microbe"},{"key":"11239_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/14622416.10.1.17","volume":"10","author":"A Llerena","year":"2009","unstructured":"Llerena, A., Dorado, P. & Pe\u00f1as-Lled\u00f3, E. M. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10, 17\u201328 (2009).","journal-title":"Pharmacogenomics"},{"key":"11239_CR14","doi-asserted-by":"publisher","first-page":"8814","DOI":"10.1021\/ac502098w","volume":"86","author":"L Cevenini","year":"2014","unstructured":"Cevenini, L. et al. Multicolor bioluminescence boosts malaria research: quantitative dual-color assay and single-cell imaging in plasmodium falciparum parasites. Anal. Chem. 86, 8814\u20138821 (2014).","journal-title":"Anal. Chem."},{"key":"11239_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.31.3.289","volume":"31","author":"KM Bertelsen","year":"2003","unstructured":"Bertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S. & Greenblatt, D. J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31, 289 (2003).","journal-title":"Drug Metab. Dispos."},{"key":"11239_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fphar.2014.00103","volume":"5","author":"AV Pandey","year":"2014","unstructured":"Pandey, A. V. & Sproll, P. Pharmacogenomics of human P450 oxidoreductase. Front. Pharmacol. 5, 103 (2014).","journal-title":"Front. Pharmacol."},{"key":"11239_CR17","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1021\/bi002135n","volume":"39","author":"A Gutierrez","year":"2000","unstructured":"Gutierrez, A. et al. Trp-676 facilitates nicotinamide coenzyme exchange in the reductive half-reaction of human cytochrome P450 reductase:\u2009properties of the soluble W676H and W676A mutant reductases. Biochemistry 39, 15990\u201315999 (2000).","journal-title":"Biochemistry"},{"key":"11239_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0006-2952(94)90022-1","volume":"47","author":"J V\u00e1squez-Vivar","year":"1994","unstructured":"V\u00e1squez-Vivar, J. & Augusto, O. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Biochem. Pharmacol. 47, 309\u2013316 (1994).","journal-title":"Biochem. Pharmacol."},{"key":"11239_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0891-5849(97)00113-5","volume":"23","author":"AR Giandomenico","year":"1997","unstructured":"Giandomenico, A. R., Cerniglia, G. E., Biaglow, J. E., Stevens, C. W. & Koch, C. J. The importance of sodium pyruvate in assessing damage produced by hydrogen peroxide. Free Radic. Biol. Med. 23, 426\u2013434 (1997).","journal-title":"Free Radic. Biol. Med."},{"key":"11239_CR20","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2013-08-520767","volume":"123","author":"R Aguilar","year":"2014","unstructured":"Aguilar, R. et al. Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood 123, 959 (2014).","journal-title":"Blood"},{"issue":"5","key":"11239_CR21","doi-asserted-by":"publisher","first-page":"eaat3775","DOI":"10.1126\/sciadv.aat3775","volume":"4","author":"Mariana De Niz","year":"2018","unstructured":"De Niz, M. et al. Plasmodium gametocytes display homing and vascular transmigration in the host bone marrow. Sci. Adv. 4, eaat3775 (2018).","journal-title":"Science Advances"},{"key":"11239_CR22","doi-asserted-by":"publisher","first-page":"244re245","DOI":"10.1126\/scitranslmed.3008882","volume":"6","author":"R Joice","year":"2014","unstructured":"Joice, R. et al. Plasmodium falciparum transmission stages accumulate in the human bone marrow. Sci. Transl. Med. 6, 244re245\u2013244re245 (2014).","journal-title":"Sci. Transl. Med."},{"key":"11239_CR23","doi-asserted-by":"publisher","first-page":"e0005365","DOI":"10.1371\/journal.pntd.0005365","volume":"11","author":"B Baro","year":"2017","unstructured":"Baro, B. et al. Plasmodium vivax gametocytes in the bone marrow of an acute malaria patient and changes in the erythroid miRNA profile. PLoS Negl. Trop. Dis. 11, e0005365 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"11239_CR24","first-page":"1118","volume":"42","author":"LG Ganousis","year":"1992","unstructured":"Ganousis, L. G., Goon, D., Zyglewska, T., Wu, K. K. & Ross, D. Cell-specific metabolism in mouse bone marrow stroma: studies of activation and detoxification of benzene metabolites. Mol. Pharmacol. 42, 1118 (1992).","journal-title":"Mol. Pharmacol."},{"key":"11239_CR25","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","volume":"6","author":"S Alonso","year":"2015","unstructured":"Alonso, S. et al. Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes. Oncotarget 6, 14905\u201314912 (2015).","journal-title":"Oncotarget"},{"key":"11239_CR26","doi-asserted-by":"publisher","first-page":"e69913","DOI":"10.1371\/journal.pone.0069913","volume":"8","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Suppression of cytochrome P450 reductase enhances long-term hematopoietic stem cell repopulation efficiency in mice. PLoS ONE 8, e69913 (2013).","journal-title":"PLoS"},{"key":"11239_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1365-2125.1985.tb02710.x","volume":"19","author":"SA Ward","year":"1985","unstructured":"Ward, S. A. et al. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br. J. Clin. Pharm. 19, 751\u2013755 (1985).","journal-title":"Br. J. Clin. Pharm."},{"key":"11239_CR28","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/AAC.00015-15","volume":"59","author":"BM Potter","year":"2015","unstructured":"Potter, B. M. et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob. Agents Chemother. 59, 2380\u20132387 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"11239_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-507","volume":"13","author":"PS Fasinu","year":"2014","unstructured":"Fasinu, P. S. et al. Enantioselective metabolism of primaquine by human CYP2D6. Malar. J. 13, 507 (2014).","journal-title":"Malar. J."},{"key":"11239_CR30","doi-asserted-by":"publisher","first-page":"e0151898","DOI":"10.1371\/journal.pone.0151898","volume":"11","author":"G Bancone","year":"2016","unstructured":"Bancone, G. et al. Single low dose primaquine (0.25mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PloS ONE 11, e0151898 (2016).","journal-title":"PloS ONE"},{"key":"11239_CR31","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/ja01623a038","volume":"77","author":"RC Elderfield","year":"1955","unstructured":"Elderfield, R. C., Mertel, H. E., Mitch, R. T., Wempen, I. M. & Werble, E. Synthesis of primaquine and certain of its analogs. J. Am. Chem. Soc. 77, 4816\u20134819 (1955).","journal-title":"J. Am. Chem. Soc."},{"key":"11239_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1021\/jm00369a031","volume":"27","author":"R Allahyari","year":"1984","unstructured":"Allahyari, R., Strother, A., Fraser, I. M. & Verbiscar, A. J. Synthesis of certain hydroxy analogs of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes. J. Med. Chem. 27, 407\u2013410 (1984).","journal-title":"J. Med. Chem."},{"key":"11239_CR33","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1126\/science.3299700","volume":"236","author":"D Walliker","year":"1987","unstructured":"Walliker, D. et al. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236, 1661 (1987).","journal-title":"Science"},{"key":"11239_CR34","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/jac\/dkv493","volume":"71","author":"S D\u2019Alessandro","year":"2016","unstructured":"D\u2019Alessandro, S. et al. A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays. J. Antimicrob. Chemother. 71, 1148\u20131158 (2016).","journal-title":"J. Antimicrob. Chemother."},{"issue":"4254","key":"11239_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, https:\/\/doi.org\/10.1126\/science.781840 (1976).","journal-title":"Science"},{"key":"11239_CR36","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/nprot.2015.128","volume":"10","author":"S March","year":"2015","unstructured":"March, S. et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat. Protoc. 10, 2027 (2015).","journal-title":"Nat. Protoc."},{"key":"11239_CR37","first-page":"115","volume":"45","author":"M Tsukamoto","year":"1998","unstructured":"Tsukamoto, M., Tampo, Y. & Yonaha, M. Lucigenin reduction by NADPH-cytochrome P450 reductase and the effect of phospholipids and albumin on chemiluminescence. Biochem. Mol. Biol. Int. 45, 115\u2013123 (1998).","journal-title":"Biochem. Mol. Biol. Int."},{"key":"11239_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1073\/pnas.98.1.81","volume":"98","author":"O D\u00f6hr","year":"2001","unstructured":"D\u00f6hr, O., Paine, M. J. I., Friedberg, T., Roberts, G. C. K. & Wolf, C. R. Engineering of a functional human NADH-dependent cytochrome P450 system. Proc. Natl Acad. Sci. USA 98, 81 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11239-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:24:20Z","timestamp":1671218660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11239-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11239"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11239-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.N.B. is a co-founder of Ascendance, which commercially manufactures and distributes micropatterned co-cultures. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3226"}}